This article needs references that appear in reliable third-party publications. Primary sources or sources affiliated with the subject are generally not sufficient for a Wikipedia article. Please add more appropriate citations from reliable sources. (December 2006)

Tercica, Inc., is a biopharmaceutical company based in Brisbane, California, USA. It is the current developer of Increlex (mecasermin [rDNA origin] injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica has applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth faiulre, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.

Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex is currently in Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD.

[edit] See also

• Human growth hormone (HGH)
• IGF-1
• IGFD
• Increlex
• Primary IGFD
• hypoglycemic seizures
• cancer

[edit] External links

This biotechnology article is a stub. You can help Wikipedia by expanding it. v • d • e

This United States corporation or company article is a stub. You can help Wikipedia by expanding it. v • d • e

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. v • d • e